Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Orexigen Therapeutics Inc. OREXQ

Healthcare Drug Manufacturers - Major
"Orexigen is an emerging pharmaceutical company, focusing on developing neuroscience drugs. The company screens older drugs seeking synergistic actions. The company's most advanced drug candidates target obesity."

Recent & Breaking News (OTCPK:OREXQ)

Wall Street Fundamentals Releases New In-Depth Stock Reports on ARIA, ARNA, EXEL and OREX

Accesswire September 11, 2013

Orexigen Therapeutics to Present at the Bank of America Merrill Lynch Global Healthcare Conference

PR Newswire September 6, 2013

Orexigen Therapeutics Prepares for the Light Study Interim Analysis Based on Direction from Data Monitoring Committee

PR Newswire August 27, 2013

Robbins Arroyo LLP Is Investigating the Directors and Officers of Orexigen Therapeutics, Inc.

PR Newswire August 12, 2013

Wall Street Fundamentals Releases New In-Depth Stock Reports on INSY, MNTA, OREX and TEAR

Accesswire July 31, 2013

Orexigen Therapeutics to Host Second Quarter 2013 Financial Results Conference Call and Webcast

PR Newswire July 26, 2013

Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference

PR Newswire July 3, 2013

Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at American Diabetes Association Annual Scientific Meeting

PR Newswire June 20, 2013

Wall Street Fundamentals Releases New In-Depth Stock Reports on ARNA, MNKD, OREX and VVUS

Accesswire May 31, 2013

Orexigen Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference

PR Newswire May 30, 2013

Orexigen Therapeutics to Present at the UBS Global Healthcare Conference

PR Newswire May 17, 2013

SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Directors of Orexigen Therapeutics, Inc.

Business Wire May 13, 2013

Orexigen Therapeutics to Present at the Bank of America Merrill Lynch 2013 Health Care Conference

PR Newswire May 10, 2013

Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2013

PR Newswire May 8, 2013

SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Directors of Orexigen Therapeutics, Inc.

PR Newswire May 7, 2013

Orexigen Therapeutics to Host First Quarter 2013 Financial Results Conference Call and Webcast

PR Newswire May 2, 2013

Orexigen Therapeutics Commends the Campaign to End Obesity's Report on Long-term Returns of Obesity Prevention Policies

PR Newswire April 25, 2013

Orexigen CEO Michael Narachi Elected to PhRMA Board of Directors

PR Newswire April 22, 2013

Morning Research on Teva Pharma, Orexigen Therapeutics, Zoetis, and Novartis

PR Newswire April 3, 2013

Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2012

PR Newswire March 13, 2013